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AbstrACt
Objective This study assessed the potential operational 
feasibility and acceptability of a heat-stable, inhaled 
oxytocin (IOT) product for community-based prevention of 
postpartum haemorrhage in Myanmar.
Methods A qualitative inquiry was conducted between 
June 2015 and February 2016 through focus group 
discussions and in-depth interviews. Research was 
conducted in South Dagon township (urban setting) and in 
Ngape and Thanlyin townships (rural settings) in Myanmar. 
Eleven focus group discussions and 16 in-depth interviews 
were conducted with mothers, healthcare providers and 
other key informants. All audio recordings were transcribed 
verbatim in Myanmar language and were translated into 
English. Thematic content analysis was done using NVivo 
software.
results Future introduction of an IOT product for 
community-based services was found to be acceptable 
among mothers and healthcare providers and would be 
feasible for use by lower cadres of healthcare providers, 
even in remote settings. Responses from healthcare 
providers and community members highlighted that 
midwives and volunteer auxiliary midwives would be 
key advocates for promoting community acceptance of 
the product. Healthcare providers perceived the ease 
of use and lack of dependence on cold storage as the 
main enablers for IOT compared with the current gold 
standard oxytocin injection. A single-use disposable 
device with clear pictorial instructions and a price that 
would be affordable by the poorest communities was 
suggested. Appropriate training was also said to be 
essential for the future induction of the product into 
community settings.
Conclusion In Myanmar, where home births are common, 
access to cold storage and skilled personnel who are able 
to deliver injectable oxytocin is limited. Among community 
members and healthcare providers, IOT was perceived 
to be an acceptable and feasible intervention for use by 
lower cadres of healthcare workers, and thus may be 
an alternative solution for the prevention of postpartum 
haemorrhage in community-based settings in the future.
bACkgrOund 
Postpartum haemorrhage (PPH) is the 
leading cause of maternal mortality world-
wide, contributing to approximately 20% of 
total maternal deaths.1 The gold standard 
uterotonic agent, oxytocin, has been shown 
to reduce the risk of PPH by 50% and is 
recommended by the WHO for administra-
tion via intravenous or intramuscular injec-
tion to every woman during the third stage of 
labour for the prevention of PPH.2 3 
Several factors currently limit widespread 
access to oxytocin in developing countries 
where the majority of PPH deaths occur.4 
In the injectable form, oxytocin is sensitive 
strengths and limitations of this study
 ►  This is the first qualitative inquiry exploring the 
operational feasibility and acceptability of a future 
heat-stable, inhaled oxytocin (IOT) product for com-
munity-based prevention of postpartum haemor-
rhage in Myanmar to inform product development.
 ► The participants involved healthcare workers and 
stakeholders from various levels of the healthcare 
system and the community and from both urban and 
rural areas to provide an insight into a range of dif-
ferent perspectives, which has been triangulated to 
enrich the findings.
 ► Since the study was conducted in selected town-
ships of Myanmar, the views and opinions towards 
IOT product may differ in other places of the country.
 ► Operational feasibility and acceptability of the IOT 
product was assessed with a similar drug delivery 
device but in the absence of the final product and 
in the context of limited experience with inhalable 
medications, which could have attributed to over-
whelmingly positive perspectives.
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to heat and must be supplied and stored under cool or 
cold conditions in order to maintain drug potency.5 6 This 
presents a significant problem particularly in rural areas 
where the availability of cold chain storage is limited. 
The necessity to administer oxytocin via an injection 
further limits widespread access to this intervention. In 
low-income and middle-income countries, a significant 
proportion of births occur outside healthcare facilities, 
in the absence of the equipment and medical personnel 
required to deliver an injection.7–9
An alternative to injectable oxytocin is misoprostol. This 
is a heat-stable oral drug, which has been recommended 
by WHO in settings where injectable oxytocin is not avail-
able. However, it is less effective with more frequent side 
effects compared with oxytocin, and thus the WHO recom-
mends that availability of misoprostol should not detract 
from efforts to make oxytocin universally accessible.2 10 In 
addition, uptake of misoprostol has faced significant chal-
lenges in some territories due to policymakers’ concerns 
around abortion misuse and reluctance for task-shifting 
of uterotonics to community-based healthcare providers 
who have been the primary target for many misoprostol 
implementation programmes.11 12
Therefore, Monash University and GlaxoSmithKline 
are currently collaborating to develop a heat-stable, easy-
to-use, low-cost, dry powder oxytocin product for respi-
ratory delivery to prevent PPH in resource-constrained 
settings.13 14 The product is being designed to simplify the 
administration of oxytocin and remove the need for refrig-
erated storage or additional consumables for administra-
tion. Inhaled oxytocin (IOT) therefore has the potential 
to extend on the value proposition of misoprostol by 
providing the gold standard uterotonic in a format that is 
suitable for use in settings where access to a reliable cold 
chain or skilled birth attendant is limited. The develop-
ment of the IOT product is currently at an early clinical 
trials stage with pharmacokinetic data in non-pregnant 
female volunteers indicating that comparable systemic 
exposure of oxytocin with that achieved following a 10 IU 
intramuscular injection can be delivered through inhaled 
delivery.14 While these data indicate that an inhaled 
product has the potential to be similarly effective to the 
current injection, further clinical trials are required and 
will be conducted to characterise the product fully and 
determine utility in low-resource settings. However, there 
are many examples of promising global health tech-
nologies that have failed to achieve significant uptake 
and impact, despite possessing the technical attributes 
required to address an unmet need.15 16 Thus, in addi-
tion to clinical efficacy, consideration must be given to 
the end-user acceptability and feasibility of product use, 
as these will be equally important drivers of the ability of 
IOT to deliver impact in target territories.
Myanmar represents a territory where the IOT product 
has the potential to improve maternal health outcomes. 
The country has one of the highest maternal mortality 
ratios in the Southeast Asian region at 282 maternal 
deaths per 100 000 live births.17 The main cause of 
maternal mortality is PPH, which is estimated to account 
for 30% of maternal deaths.18 Approximately 70% of 
the population resides in rural areas and the majority 
of the childbirths occur at home.19 The health system in 
Myanmar is divided into central-level, state/division-level 
and township-level services. At the township level, health-
care services are provided through a township hospital, 
station hospital, rural health centres and subrural health 
centres. A township medical officer is responsible for 
administrative and clinical decision making. Maternal 
and child health services at the subcentre and communi-
ty-level are provided by a midwife (MW). Due to shortages 
in MWs, a volunteer cadre of auxiliary midwives (AMWs) 
at the community-level support the MWs with provision 
of maternal and child health services, including care for 
uncomplicated deliveries.
Approximately one-third of all deliveries in Myanmar 
are attended out-of-facility settings by an MW or AMW.20 
However, these providers have limited capacity to actively 
manage the third stage of labour.21 22 Government policy 
prohibits MWs and AMWs from delivering injections 
outside of the health facility setting and thus currently 
MWs (but not AMWs) are authorised to use misoprostol 
for routine prevention of PPH and can only deliver an 
injection of oxytocin for ‘life-saving’ purposes. AMWs 
face further restrictions and are generally not authorised 
to use any medications to manage childbirth or PPH.21 In 
the absence of national policy allowing these providers to 
use injectable oxytocin, access to gold standard measures 
for the prevention of PPH is limited.21 Furthermore, the 
ability of MWs and AMWs to maintain a consistent cold 
chain for oxytocin is severely limited as most rural health 
centres or subcentres are not equipped with cold storage 
facilities.23 Thus, out-of-facility deliveries attended by 
MWs or AMWs represent a setting where IOT could be 
beneficial through expanding access to first-line therapy 
and obviating the need for cold storage.
To guide product development and implementation 
planning activities, this study assessed the operational 
feasibility and acceptability of IOT for improving commu-
nity-based care in Myanmar.
MethOds
A qualitative inquiry using focus group discussions and 
in-depth interviews was conducted to gain insight into 
the perspectives of healthcare providers, community 
members and key informants. Methods are reported 
according to the Consolidated Criteria for Reporting 
Qualitative Research checklist.24
study setting and participants
Three administrative areas in Myanmar, South Dagon, 
Ngape and Thanlyin townships, were purposively selected 
for the study, based on their geographic location (rural/
urban) and extent of use of the AMW cadre, and after 
discussion with Ministry of Health officials. South Dagon 
is an urban township and has a population of 297 000 with 
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one 50-bed township hospital, one station hospital and 
two urban health centres. Thanlyin is a large township, 
which has both urban and rural characteristics and has 
a population of 188 000 with a 150-bed district hospital, 
one station hospital and five rural health centres. Ngape 
is a rural township and has a population of 46 500 and 
has one 25-bed township hospital, one station hospital, 
two rural health centres and 14 subcentres. South Dagon 
and Thanlyin are located in Yangon region, where an 
average of 94.6% of women engage a skilled provider 
(including an MW) for antenatal care and the average 
number of visits is approximately four.22 25 While only 
65.4% of women give birth in a health facility, coverage of 
skilled attendance at birth is 82.5%.22 Ngape is situated in 
Magway region, where 82.5% of women engage a skilled 
provider for antenatal care and the average number of 
visits is four.22 25 Only 37.5% give birth in a health facility, 
however, 68.4% engage a skilled provider and a further 
6.8% of deliveries are attended at home by an AMW.22
A total of 16 in-depth interviews and 11 focus group 
discussions were conducted involving 100 persons. Focus 
groups had between 5 and 10 participants and included 
a total of 26 MWs, 28 AMWs and 30 mothers with a child 
aged less than 3 years. In-depth interviews consisted of 
healthcare providers at the township level, obstetricians 
from both the public and private healthcare system and 
other key informants from the pharmaceutical industry 
and agencies working on maternal and child health. Key 
informants were selected on the basis of their knowledge 
and experience with the local health system and thus 
could provide insights into the considerations for new 
product introduction.
research team and data collection
The research team was led by an experienced qualita-
tive Myanmar researcher. All six team members (three 
were medical doctors and the others had worked in the 
medical field) had previous experience with qualitative 
data collection. Apart from one, all were women. A 4-day 
training was given to all researchers on background, 
objectives and design of the study, and data collection, 
management and analysis methods. None of the research 
team members had a prior relationship with study partic-
ipants. Rapport with the participants was built during 
focus group discussion through self-introduction and 
explaining the research objectives.
Data collection for in-depth interviews was mostly 
conducted in the participants’ office as the place of 
choice by the interviewee ensuring confidentiality and 
convenience. Focus group discussions with MWs, AMWs 
and mothers were conducted in comfortable private 
places where confidentiality and privacy were ensured. 
Separate FGDs were conducted for different categories 
of participants. Question guides were used to investi-
gate the practices around childbirth, beliefs around 
PPH and bleeding, perspectives of medications around 
the time of birth, oxytocin current practices, perspective 
towards IOT and possible implementation strategies. In 
all interviews and focus groups, only after the discussion 
moved towards management of PPH, the moderator gave 
a brief description of IOT. To aid in the description of the 
product, a Rotahaler device was shown as an example of 
a low-cost, passive inhaler, which could be used for inhal-
able oxytocin.
The duration of the focus groups and interviews ranged 
from 30 min to 90 min, and most were conducted in 
Myanmar language. Data were collected until it was felt 
that data saturation was obtained. All the focus group 
discussions were audio-recorded using a digital recorder. 
For the in-depth interviews, apart from three obstetri-
cians and two key informants from the pharmaceutical 
industry who declined to be digitally recorded, all others 
were digitally recorded. Contemporaneous notes were 
taken for all discussions and interviews.
data management and analysis
All Myanmar language interviews and focus group discus-
sions were transcribed in Myanmar language by the note 
taker for the focus group discussions and by the inter-
viewer for the in-depth interviews and were checked 
against the notes for consistency and validity. Transcripts 
were translated into English by a translator and checked 
against the Myanmar transcripts to ensure the quality and 
the meaning of the original transcripts was not lost. To 
aid the analysis, NVivo (V.11, VMWare) software was used. 
Three data analysts coded the transcripts. Reliability 
coding was set at 80% agreement, and the inter-coder reli-
ability was found to be over 80%. This approach balanced 
the differing views of the researchers in the study. Partic-
ipant characteristic codes (obstetricians, hospital staff, 
MWs, AMWs and mothers) and setting codes (urban and 
rural) were also considered during the coding process. 
Before finalising the code structure, all the researchers 
who coded the transcripts collaboratively reviewed and 
agreed on the final structure. Qualitative content analysis 
using both inductive and deductive approaches was used 
in interpreting the findings.
Patient and public involvement
This study sought to understand the perceptions of 
community members, healthcare providers and key infor-
mants towards the conceptual acceptability and feasibility 
of an IOT product for the prevention of PPH in commu-
nity settings of Myanmar. No intervention was tested as 
part of this research, and the participants are not formally 
considered ‘patients’ in that they are not seeking or 
receiving medical care as part of this study.
However, the research described here is in itself a 
strategy to increase patient and public involvement in 
research. Through the conduct of this study, the product 
development team has created a mechanism by which the 
design and future implementation of the IOT product 
can be informed by the priorities, experiences and pref-
erences of the target population for the product (ie, 
mothers and healthcare providers).
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While the design, recruitment and conduct of this study 
was not directly informed by members of the public who 
represent the participant groups involved, findings from 
the study were disseminated back to the public through 
the conduct of a half day workshop in March 2017, which 
was attended by healthcare providers, government offi-
cials and members of the pharmaceutical industry.
ethics
Written informed consent was obtained from all partic-
ipants, all of whom were reimbursed for the actual cost 
of travel plus a daily allowance to cover meal costs (3000 
kyats, equivalent to US$2.5).
Findings
Current perceptions and practices towards PPh in community 
settings
Cultural beliefs towards postpartum bleeding
Regardless of the place of residence, many women in the 
study preferred home births over facility births, mainly 
because of cost, the supportive family environment and 
inconvenience of engaging a facility. Women in the study 
described postpartum blood as ‘bad’ or ‘impure’ and 
explained that it was essential to remove this blood from 
the body in order to avoid subsequent pain or hardship. 
This viewpoint seemed more common among participants 
from rural areas as compared with their urban counter-
parts. A traditional oral medicine named ‘Memakin say’ 
was commonly used in the first 3 days after delivery to 
facilitate bleeding and clean the body.
You see, we have to carry the pregnancy for 9 to 10 
months and the bad blood accumulated in our body 
for so long. So with the birth of the baby, it should 
all come out… or else if it stays in our body, we will 
not be healthy. So bleeding is a necessity for us after 
delivery. If it does not come out…. pain in supra-pu-
bic area will occur. (33-year-old mother of three, rural 
area)
Despite traditional beliefs surrounding postpartum 
bleeding, a prominent theme during discussions with 
mothers was the trust placed in the formal health sector 
for matters relating to maternal health. In general, rural 
participants saw community-based providers, such as 
MWs and AMWs, as the key decision makers or advisers 
for health, whereas participants from urban areas seemed 
to place more reliance on staff at healthcare facilities. For 
the majority of women in the study, MWs and AMWs were 
the main home birth attendants with occasional births 
attended by traditional birth attendants.
Burden of PPH, its management and associated challenges
Alongside the perception of the need to expel bad blood, 
excessive blood loss after childbirth was also cited as a 
danger by many community members and two mothers 
participating in the study had personally experienced 
excessive bleeding postpartum.
We are afraid sometimes that after the birth of the 
baby, bleeding might occur. (33-year-old mother of 
four, rural area) 
Mothers who had seen postpartum bleeding explained 
that dangerous levels of bleeding were recognised by 
monitoring how quickly a sarong (a traditional wrapped 
skirt for women) became soaked with blood. While many 
healthcare providers suggested that PPH is rare, others 
spoke of the serious nature of the condition and described 
excessive bleeding like a ‘pipe water falling from a pipe-
line’. AMWs often described the challenges associated 
with PPH management in the context of their restricted 
authority to administer medications and their reliance on 
MWs who were often not readily accessible.
I know bleeding is serious and the mother can die, 
but what shall we do apart from waiting. It was so long 
waiting for her (the MW) to arrive. I dare not to give 
injection. I am afraid of someone seeing me giving an 
injection to the patient. (AMW, rural area) 
Another challenge faced by community-based home 
birth care providers is the law restricted towards injection. 
Healthcare providers explained that the current narcotic 
law in Myanmar restricts use of injections by MWs and 
AMWs such that they are prohibited from routinely 
delivering an oxytocin injection for the prevention of 
PPH when attending out-of-facility deliveries. However, 
in practice, some MWs are administering an injection of 
oxytocin with authorisation from the residing township 
medical officers due to the live-saving potential of the 
drug. In practice, the absence of national law author-
ising both MWs and AMWs to deliver injectable oxytocin 
restricts widespread use of oxytocin for PPH prevention.
 Another problem is that in our country, the narcotics 
laws do not allow the midwives to give (medicines in) 
injection form. So if we can avoid the injection form, 
and then we can use it (oxytocin)…and then it is defi-
nitely useful for prevention of PPH. (Obstetrician in 
private practice, urban area) 
Access to quality oxytocin in community settings
Prevention and management of PPH was mainly 
performed by MW at the community level in which injec-
tion oxytocin was used. However, reliability and avail-
ability of the cold storage required to maintain oxytocin 
quality within the settings of community-based care was 
limited. Refrigerators were not available at rural health 
centres and subcentres, which are designed as the bases 
for community-based MWs. Community-based providers 
can keep items cold for short periods using ice bricks 
(supplied from the nearest township hospital) in vaccine 
transport carriers, but they explained the difficulty they 
would face if they were to maintain consistent refrigera-
tion for oxytocin.
We have to buy the ice in the city and there must 
be electricity to keep it cool. In the rainy season, it 
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[keeping oxytocin cold] would not be feasible. (MW, 
rural area) 
In settings where cold storage facilities are available, 
unreliability of electricity supply was cited as a barrier, 
with frequent power outages and voltage fluctuation. 
Since most of the injection oxytocin were not kept in a 
cold storage, which may have effect on the quality.
Acceptability and feasibility of iOt
Conceptual acceptability
Acceptability was explored through the perceived need 
for and willingness to use the IOT product when avail-
able. Although general acceptance of all forms of medica-
tion prescribed by healthcare providers was high among 
the community, injections stood out to be most preferred 
due to their perceived rapid action. Positive views towards 
inhalers were also expressed by community members, 
who cited ease of use and a believed rapid onset of action 
as benefits. One woman saw the inhalant as a less painful 
alternative to injections.
We don’t need to drink it and it does not hurt 
like an injection, I think the inhaler will be really 
good. (23-year-old mother, urban area) 
A key informant from the pharmaceutical industry 
expressed concerns about the acceptability of the IOT 
product to community members, as past introduction 
of a dry powder inhaler for asthma had failed to result 
in sustainable uptake in Myanmar. This informant spec-
ulated that this was due to patients’ concern about 
inhaling powder into the lungs. However, this concern 
was not heard from community members participating in 
this study and most mothers expressed their willingness 
to accept IOT compared with oral and injectable drugs. 
Some concerns were expressed by a minority of these 
stakeholders, most commonly, they worried whether they 
would know the correct time at which to use the drug, 
fearing that they would inhale too early (before the baby 
is delivered).
Mothers and healthcare providers alike expressed a 
strong desire for a single-use device packaged within 
a sealed sachet to keep it ‘sterile’ and to prevent trans-
mission of infections. Although there was no prefer-
ence to the colour, the smell of the drug was thought to 
have a significant impact on acceptability. Several MWs 
and AMWs and one obstetrician suggested that mothers 
would be reluctant to inhale the drug if it has a strong 
or unpleasant odour. However, there were some mothers 
who explained that while a ‘soft’ smell would be favoured, 
they would be willing and able to inhale the IOT product 
regardless, if it was important for their health.
Some MWs and AMWs held concerns about the feasi-
bility of a mother inhaling from a device immediately 
after delivery, fearing the woman may be too tired. They 
suggested that only one inhalation or potentially a few 
with not too much force would be feasible for postpartum 
women. Other healthcare providers disputed this idea 
and suggested that mothers would be completely able to 
use the inhaler as shown. This viewpoint was supported 
by mothers themselves, many of whom declared that they 
would have no problem using the device after delivery. 
Following a demonstration of the Rotahaler device 
during the interviews and focus groups, both community 
members and healthcare providers remarked on the ease 
of use of the inhaler.
This ease of administration was highlighted as a benefit 
of the IOT product for MWs and AMWs attending home 
births, who are often alone and struggle to manage all 
aspects of maternal and neonatal care that are required 
during the early postpartum period.
Actually, that (IOT) is more comfortable. It also re-
duces work. The injection to the butt will be like: 
open it, put it and such. This will be like open and can 
just say to the patient to inhale it by herself. (AMW, 
urban area) 
Healthcare providers, especially the obstetricians, 
emphasised that the product should first be demon-
strated to be effective with few side effects before it would 
be accepted by either themselves or the community. They 
suggested that assurance of safety and efficacy could 
come from WHO recommendations or from proven clin-
ical trials before introduction of the product into routine 
clinical care.
Although I think IOT is useful, the best thing is to 
wait for the WHO package. They will have some trials 
and then they will find out the potency and efficacy 
and then safety and then after that they will recom-
mend to use in developing countries. (Obstetrician 
in private practice, urban area) 
Administration of IOT
MWs and AMWs attending home births were suggested 
as suitable providers for the introduction of IOT. MWs 
were seen as possessing the skills and knowledge required 
for them to safely and effectively administer the drug or 
instruct the mother or a relative to do so. The ease of use 
of the IOT product was also thought to offer the poten-
tial to relieve the burden on MWs as they are often alone 
when attending deliveries in the community.
MW 4: ‘We can do our management better [with 
IOT] during birth’.
MW 9: ‘ … [W]e can ask someone to help us give the 
inhalation to the mother, but we cannot do this with 
an injection as it needs a healthcare provider with 
skill to do it’. (FGD with MWs, urban area) 
Opinions towards task-shifting IOT administration to 
AMWs were mixed among healthcare providers. In hard-
to-reach areas, AMWs, who often reside in the remote 
villages, were suggested as a more accessible provider of 
essential care in the absence of an MW. Some MWs and 
obstetricians were in support of IOT use by AMWs and 
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suggested that, particularly in remote areas, it would be 
necessary to allow AMWs direct access to the product.
I think it should be in the hands of AMW, especially 
in the hilly regions. In emergency situations mothers 
don’t have anyone to rely on. (MW, rural area) 
MWs themselves explained that they often attend deliv-
eries in the absence of an MW, and in this situation, a 
non-injectable medication, such as IOT, would provide 
them the opportunity to protect the mother from a 
potentially fatal PPH.
Conversely, some of the township-level providers and 
MWs expressed their concern about the possibility of 
AMWs misusing IOT during delivery to augment labour, 
a practice suggested to be common among AMWs in the 
past. However, there were also suggestions that release of 
IOT with clear instructions and rebranding as a product 
indicated for postpartum use only (unlike the injection), 
could benefit women and community-based providers. 
One AMW suggested that the perception of oxytocin as a 
drug for augmenting labour is associated specifically with 
the injection and so may not be automatically applied to 
the inhaler.
Moderator: ‘Do people consider it [IOT] as a uterus 
opening drug?’.
AMW: ‘They think injection will open the uterus, not 
an inhaler, so I think it is ok’. (FGD with AMWs, rural 
area) 
Regarding community distribution of IOT to mothers, 
the responses varied widely between the community and 
the healthcare providers. Mothers supported the idea, 
explaining that it would ensure they have the product 
regardless of where they deliver and who attends them.
It would be more convenient if you can give it to the 
mothers, then we won’t need to worry about getting 
the drug in time. Even if the Sayarma (MW) did not 
arrive in time, we can still use it after the delivery of 
the baby. It would be really useful. (28-year-old moth-
er of three, rural area) 
In contrast, healthcare providers were more opposed 
to community distribution of IOT due to the fact that 
mothers may use the product before labour or delivery. 
Some mothers and healthcare providers suggested that 
community distribution of IOT should be selective and 
targeted specifically to mothers in hard-to-reach areas, as 
they are most likely to be at risk of delivering outside a 
facility or in the absence of a skilled provider. In general, 
a prominent opinion among community members and 
healthcare providers was that particular care was needed 
for community distribution of IOT.
Training
While there was some awareness of orally inhaled medi-
cines among community members, none of the mothers 
participating in this study had personally used an oral 
inhaler. As such, all stakeholders stressed the importance 
of training mothers how to use the inhaler. All participants 
suggested that training for mothers on IOT should start 
during the antenatal period. They emphasised that early 
exposure to the device would be beneficial for mothers to 
understand its function and intended use. The local MW 
of each village was suggested as the most suitable person 
for training the mother.
For the training of healthcare providers, sugges-
tions centred on the necessity to conduct systematic 
training to ensure all cadres of healthcare providers 
are adequately educated about the IOT product. In the 
current model, healthcare workers are trained through 
a cascade system, beginning with a training of trainers 
workshop at the national level and thereafter through 
states/regions, districts, townships and finally down to 
the community-level health workers. However, some MWs 
complained that this mechanism of training can result in 
messages being inaccurately or ineffectively passed down 
through the chain. Several MWs suggested that direct 
training where they can interact with teachers at the 
central level would be preferable to them. Additionally, 
a trainer at national level explained that the feasibility 
of conducting coordinated nationwide training would 
depend on finances and supplies. The suggested training 
content included indication for use, contraindications, 
side effects, possibility of repeated dose and storage 
requirements.
Clear instructions on the purpose of the drug, how to 
use the device and possible side effects either written in 
Myanmar language or pictorially depicted were suggested 
by some mothers and healthcare providers.
IOT pricing
Reports from mothers and healthcare providers partici-
pating in this study suggested that in recent years, drugs 
and services are provided free of charge for women deliv-
ering in healthcare facilities. For out-of-facility deliveries 
attended by MWs, many of the respondents in the study 
mentioned that women pay for delivery with cash or gifts 
but that drugs such as oxytocin are not purchased directly 
by patients. This suggests that patients’ out-of-pocket expen-
diture for oxytocin is currently minimal, and therefore, 
IOT may likewise be provided free of charge to end-users. 
However, some healthcare providers expressed concerns 
over the sustainability of current levels of government 
health financing, and thus, the possibility that user charges 
will be applied to IOT should be considered. As such, 
participants were asked to suggest a price for IOT to ensure 
its affordability in the event that patients are required to 
directly purchase the product. Most stakeholders felt that 
a price between 500 and 1000 kyats (US$0.40–US$0.80) 
would be most affordable to community members and that 
not more than 500 kyats (US$0.40) would be necessary to 
also ensure affordability to low-income families.
disCussiOn
To understand the acceptability and feasibility of imple-
menting IOT in Myanmar, a situation assessment was 
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conducted to explore current attitudes and practices 
towards childbirth, PPH and oxytocin. IOT acceptability 
was explored from the point of view of community 
members and healthcare providers, while perspectives 
of all stakeholders were used to understand the opera-
tional feasibility. Responses to the IOT product were 
overwhelmingly positive from community members, all 
of whom expressed an unconditional acceptance of the 
product and praised its ease of use. These expressions 
of acceptance may in part be due to an appreciation for 
a product that replaces an injection, as the fear of pain 
associated with injectable products was a concern for 
some community members. Additionally, community 
members who were familiar with inhalers generally held 
positive views towards this route of administration, due 
to the rapid relief that is experienced after use of these 
medications for respiratory conditions (such as asthma). 
However, there may also be an element of social desir-
ability bias in participant responses, and acceptability 
of the product to community members should be criti-
cally evaluated. For example, a barrier to the accept-
ability of IOT may arise from existing traditional beliefs 
and practices, which encourage expulsion of blood after 
childbirth. Community members may therefore resist a 
product that controls or reduces postpartum blood loss. 
However, many mothers from both urban and rural areas 
expressed concerns about excessive bleeding after child-
birth, attitudes that could be harnessed to facilitate accep-
tance of IOT as a product for preventing dangerous levels 
of bleeding. Furthermore, community members predom-
inantly place their trust in the healthcare system, particu-
larly in MWs. Thus, it is likely that advice from MWs and 
other healthcare providers will dispel potentially inhib-
iting attitudes and facilitate community acceptance of 
IOT. These findings will help inform the design of educa-
tion strategies in order to improve acceptability to benefi-
ciaries. Specifically, for these settings, it will be important 
to inform community members about IOT in a way that is 
sensitive to existing beliefs, harnessing and encouraging 
enabling attitudes (such as recognition of the danger of 
excessive blood loss) and mitigating the impact of poten-
tial barriers (such as the traditional belief for the need of 
postpartum blood loss). Identification of the MW as a key 
advisor for health highlights that these providers would 
likely be an effective channel through which this informa-
tion could be delivered to the community.
Among healthcare providers, opinions about IOT were 
predominantly positive, particularly in relation to ease of 
use. However, remarks from healthcare providers were 
often tempered with expressions of concern or appre-
hension. Given that IOT uses a different administra-
tion route, many providers expressed their desire to be 
assured of its efficacy and safety. Robust evidence of safety 
and efficacy will be generated as part of the regulatory 
requirements for the product. Attitudes of healthcare 
providers expressed in this study highlight the impor-
tance of making this data readily available to promote 
acceptance.
In addition to the safety and efficacy of the product, 
a common concern among healthcare providers was 
whether the device could be operated correctly to deliver 
the required dose to the patient. In this regard, care will 
need to be taken to ensure that community members can 
be appropriately trained on how to use the device given 
that the utility of the IOT product may to some degree be 
dependent on their participation in drug administration.
Given that home births remain common in Myanmar, 
we explored the acceptability of IOT use in these settings, 
with particular consideration for the possibility of product 
use by MW or AMW, who are the common attendants of 
out-of-facility deliveries. Most stakeholders suggested that 
IOT would be both appropriate and beneficial for use 
by MWs at out-of-facility deliveries. Healthcare providers 
suggested that MWs possessed the skills and knowledge 
required to administer the drug or instruct the mother 
or relative on administration. At a policy level, a non-in-
jectable form of oxytocin aligns with both national 
drug law (which prohibits MWs use of injections) and 
standard treatment guidelines (which prioritise use of 
oxytocin over misoprostol for prevention of PPH). Atti-
tudes towards the acceptability of product use by AMW 
were more varied. Although current policy states that 
AMWs are only to assist MWs, staff shortages and extreme 
geographic barriers severely limit accessibility of MWs, 
and as a result, AMWs are often required to act as the 
sole attendant for out-of-facility deliveries in rural remote 
areas.21 26 However, national policy currently prohibits use 
of uterotonics by AMWs, and many stakeholders partici-
pating in this study had reservations about tasking-shifting 
IOT to these providers.27 Objections were primarily based 
on fears that the drug would be misused for the induction 
or augmentation of labour, which was reported to be a 
common practice among AMWs in the past. In contrast, 
there were some stakeholders, including township-level 
policymakers, who suggested that the knowledge and 
skill set of AMWs is improving over time and that these 
providers should be considered for IOT administration. 
Training for end-users can be considered in the context of 
training healthcare providers and community members 
in the use of IOT. The coordinated chain of training 
down the hierarchy of healthcare providers currently in 
place in Myanmar was described as a means to efficiently 
and effectively ensure all healthcare providers in the 
country receive appropriate training. However, assuring 
the consistency of these trainings may be a challenge and 
may require both financial and system support.
Training pregnant women and their families through 
antenatal care appears to be highly feasible as coverage 
of at least one antenatal visit among women in Myanmar 
is high (81%).22 However, given the expressed unfamil-
iarity of community members towards inhalers, repeated 
trainings may be necessary. Compared with one antenatal 
visit, attendance of at least four sessions is less common, 
particularly in rural areas where 51% of women attend 
at least four visits, compared with 84% of their urban 
counterparts.22 Thus, mechanisms to ensure adequate 
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comprehension of device operation among community 
members, for example, through the use of hands-on 
training exercises, will be a critical aspect of product 
introduction strategies. Additionally, this study suggests 
that there is a strong degree of community trust in and 
compliance with the advice of healthcare providers, 
further highlighting the availability of effective channels 
for community education.
COnClusiOn
This study has uncovered a variety of factors that can be 
considered for the operational feasibility and accept-
ability of IOT product in community-based care settings 
in Myanmar. Use of IOT at community births attended by 
a MW was acceptable to most stakeholders, and the ease 
of product use, heat stability and non-injectable delivery 
route were considered to be the major facilitators. Further 
decentralisation of services to AMWs could further 
increase uptake of IOT, particularly in remote rural 
areas. The trust community members place in healthcare 
personnel, particularly community-based providers, may 
help facilitate community acceptance of IOT. Ensuring 
comprehensive training to community-based providers 
and mothers through participatory approaches starting 
from the antenatal period will also enhance the opera-
tional feasibility of the IOT product into the community.
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